tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Thomas Smith, 56 are a BUY (74.67%), 19 are a HOLD (25.33%).
Analyst Thomas Smith, currently employed at LEERINK, carries an average stock price target met ratio of 44.87% that have a potential upside of 33.8% achieved within 115 days.
Thomas Smith’s has documented 139 price targets and ratings displayed on 25 stocks. The coverage is on Healthcare, Industrials sectors.
Most recent stock forecast was given on RAPT, RAPT Therapeutics at 21-Feb-2024.
Analyst best performing recommendations are on AXLA (AXCELLA HEALTH).
The best stock recommendation documented was for AXLA (AXCELLA HEALTH) at 12/15/2022. The price target of $6 was fulfilled within 1 day with a profit of $4.98 (45.36%) receiving and performance score of 453.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$3
$1.84 (158.62%)
$3
1 months 25 days ago
(26-Sep-2024)
0/4 (0%)
$2.42 (417.24%)
Hold
$7
5 months ago
(20-Jun-2024)
1/3 (33.33%)
$0.45 (6.87%)
57
Sell
$1
$-0.16 (-13.79%)
$1.5
10 months 3 days ago
(17-Jan-2024)
6/6 (100%)
$-0.02 (-1.96%)
278
Buy
11 months 2 days ago
(18-Dec-2023)
1/1 (100%)
$32.69 (83.16%)
358
Buy
$9
$7.84 (675.86%)
1 years 6 months 9 days ago
(11-May-2023)
2/4 (50%)
$4.84 (116.35%)
178
What Year was the first public recommendation made by Thomas Smith?
